Sumitomo Pharma Oncology, Inc.

Sunovion Pharmaceuticals Inc.

Sumitomo Dainippon Pharma Oncology, Inc.

Takahiko Hashizuka

Hiroaki Tanaka

Adam Siddiqui-Jain

Shuji Masumoto

Hirotaka Kurebayashi

Paul Flynn

Yuka Arikawa

Yuji Fujiwara

John R Snoonian

Harold Scott Wilkinson

Haitao Zhang

Robert Joseph Prytko

Nandkumar Nivritti Bhogle

A crystalline form and/or polymorph of a compound having the following structure (I), including tautomeric and zwitterionic forms thereof, are provided: Methods associated with preparation and use of the polymorphs, and pharmaceutical compositions comprising the same are also provided. Also provided are methods for preparing a compound having formula (I), or a salt, tautomer or zwitterionic form thereof.

CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer

The present disclosure relates to salts of (R)-1-(8-fluoroisochroman-1-yl)-N-methylmethanamine, crystalline forms thereof, and methods of preparation thereof, which are useful in the treatment of CNS disorders.

Salts of a heterocyclic compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof

Growing community of inventors

Matsubara, Japan

Takahiko Hashizuka